Trilogy Events

Clinical Development Think Tanks

Trilogy holds regular Think Tanks for senior industry colleagues and thought leaders to gather and discuss key issues facing the Industry. Each Think Tank begins with a presentation about current evolutions or constraints in a particular area of clinical development. This is followed by an open and lively discussion about what we, as a group, think the industry can be doing to take advantage of the evolutions or improve upon the constraints. The goal is to share knowledge and experience, and together come up with ideas for how we can improve the many different processes involved in product life cycles. The Think Tank series covers a different topic each time. To minimise the effect on your working day, we run the Think Tanks as breakfast meetings (9:00-12:00), and also offer a light breakfast. There is no cost to participate, all you need to do is bring your ideas and join in the discussion.


Upcoming Think Tanks

Measuring the Service of Medical Writing

Trilogy will be holding its next Think Tank on 31 October in Raleigh, NC, US. We will be discussing the challenge of measuring the service provided for medical writing – how do you define a good quality document and how do you measure the activities performed by medical writers. The Think Tank will be kicked off by presentations from Dr. Shari Bodnoff (Global Head of Operations, Regulatory Writing and Submissions at Novartis) and Dr. Julia Forjanic Klapproth (Senior Partner at Trilogy Writing & Consulting), before we dive into a round-table discussion. Please contact us to arrange your participation in the Think Tank.

PBRERs and RMPs

On 14 November, Trilogy will be holding a Think Tank at the BMA House in London. This time we will be discussing “PBRERs and RMPs – Main Challenges and Reviewer Insights” amongst a small group of peer experts. The Think Tank will be kicked off by presentations from Dr. Stephanie Millican (Medicines and Healthcare products Regulatory Agency, MHRA) and Dr. Lisa Chamberlain James (Senior Partner at Trilogy Writing & Consulting), before we dive into a round-table discussion. Please contact us to arrange your participation in the Think Tank.

Clinical Development Plan

On 14 December, Trilogy will be holding a Think Tank in the Villa Kennedy in Frankfurt. We will be discussing Clinical Development Plans and how these documents help obtain the most painless and efficient approvals possible. The Think Tank will be kicked off by presentations from Dr. Katrin Bernöster (Vice President of Corporate Project & Portfolio Management at Biotest AG) and Dr. Barry Drees (Senior Partner at Trilogy Writing & Consulting), before we dive into a round-table discussion. Please contact us to arrange your participation in the Think Tank.


Past Think Tanks

29 November 2016: MEASURING THE QUALITY OF MEDICAL WRITING – Think Tank in London

Trilogy hosted a discussion on the challenge of measuring the service provided for medical writing – how do you define a good quality document and how do you measure the activities performed by medical writers, together with our speakers:

  • Wayne Beazley (Director Medical Writing at Astellas Pharma)
  • Dr. Julia Forjanic Klapproth (Senior Partner at Trilogy Writing & Consulting)

12 July 2016: RISK MANAGEMENT PLANS AND SUMMARY FOR THE LAY READER – Think Tank in Frankfurt

Trilogy hosted a discussion on every-day challenges involved in meeting the guideline on good pharmacovigilance practices (GVP), the challenge of writing and managing Risk Management Plans (RMPs), including the newly legislated Part VI.2 of the RMP (summary for the lay reader), and focused also on the potential changes and challenges posed by the updated guideline in consultation, together with our speakers:

  • Sven Schirp (Head of Global Pharmacovigilance Writing at Boehringer Ingelheim)
  • Lisa Chamberlain James (Senior Partner at Trilogy Writing & Consulting, UK)

15 December 2015: THE PATIENT’S VOICE THROUGH SOCIAL MEDIA – Think Tank in London

Trilogy hosted a discussion on “Are we ready for the patient’s voice through social media in the benefit-risk assessment of drugs?” amongst a small group of peer experts and together with our speakers:

  • Phil Tregunno (Signal Management and Quality Standards Unit Manager at MHRA)
  • Sue Rees (EU QPPV, Executive Director at Amgen)

3 November 2015: MEASURING THE QUALITY OF MEDICAL WRITING – Think Tank in Frankfurt

Trilogy hosted a discussion on the challenge of measuring the service provided for medical writing – how do you define a good quality document and how do you measure the activities performed by medical writers, together with our speakers:

  • Chris Wichems (Director, Medical Writing and Disclosure, Clinical Research & Development at CSL Behring)
  • Dr. Julia Forjanic Klapproth (Senior Partner at Trilogy Writing & Consulting)

18 June 2015: GOOD PHARMACOVIGILANCE PRACTICES – Think Tank in London

Trilogy hosted a discussion on the challenges posed by the guideline on good pharmacovigilance practices (GVP) with a special focus on Risk Management Plans (RMPs), together with our speakers:

  • John Solomon (Head of Pharmacovigilance at Sanofi)
  • Dr. Lisa Chamberlain James (Senior Partner at Trilogy Writing & Consulting)

23 April 2015: MARKET ACCESS AND REIMBURSEMENT – Think Tank in Frankfurt

Trilogy hosted a discussion during which we explored strategies for how to make sure that your Clinical Development Programme meets not only the needs for regulatory approval, but also the needs for market access and reimbursement, together with our speakers:

  • Dr. Boris Pfeiffer (Director Global Evidence & Value Development, Merck, and representative in the IMI GetReal project)
  • Dr. Thomas Wagner (Medical Writing Manager at Trilogy Writing & Consulting)

‘very interesting… and thought-provoking discussion’

‘very pleasant and fruitful event’

‘thoroughly enjoyed… and incredibly useful’

‘helpful and informative… I learned very much’

‘interesting discussion’

‘several valuable thoughts’